Lunai Bioworks/$LNAI
1D1W1MYTD1Y5YMAX
Capital at risk
About Lunai Bioworks
Lunai Bioworks Inc is a biopharmaceutical company. Through its subsidiaries, it is mainly focused on developing allogeneic cell and gene therapies to promote stronger immune system responses, potentially for long-term or life-long cancer remission in some of the deadliest cancers. The group is engaged in the development of RENB-DC11 and RENB-DC20 (potential cell therapeutic vaccine candidates for different types of cancer); a proprietary AI platform that analyzes genetics to provide earlier and more accurate cancer diagnosis; and machine learning pipelines that harmonize and analyze complex, heterogeneous datasets to uncover clinically actionable insights. The group's reportable segments are: RENB, BioSymetrics, and RENC. Geographically, it operates in the United States and Netherlands.
- Ticker
- $LNAI
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 29
- Headquarters
- Los Angeles, United States
- Website
- www.lunaibioworks.com
Lunai Bioworks Metrics
BasicAdvanced
$11M
-
-$46.23
0.35
-
Price and volume
Market cap
$11M
Beta
0.35
52-week high
$5.02
52-week low
$1.91
Average daily volume
38K
Financial strength
Current ratio
0.194
Quick ratio
0.164
Long term debt to equity
-0.014
Total debt to equity
-0.148
Interest coverage (TTM)
-18.24%
Profitability
EBITDA (TTM)
-9.77
Gross margin (TTM)
100.00%
Net profit margin (TTM)
-612,568.11%
Operating margin (TTM)
-47,113.88%
Management effectiveness
Return on assets (TTM)
-9.65%
Return on equity (TTM)
-325.46%
Valuation
Price to revenue (TTM)
308.896
Price to book
-1.09
Price to tangible book (TTM)
-0.67
Price to free cash flow (TTM)
-1.23
Free cash flow yield (TTM)
-81.31%
Free cash flow per share (TTM)
-1.894
Growth
Earnings per share change (TTM)
36.57%
3-year earnings per share growth (CAGR)
-33.27%
Upcoming events
No upcoming events
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.